Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9316469 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL14138278 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL10344379 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL10344454 | 0.98 | MEN1 (0.52) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL6879144 | 0.95 | MEN1 (0.52) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL11550525 | 0.93 | MEN1 (0.48) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL11552723 | 0.91 | MEN1 (0.47) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL26695813 | 0.90 | KMT2A (0.47) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL8105477 | 0.89 | MEN1 (0.48) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL18350198 | 0.87 | MEN1 (0.57) | MEN1KMT2AKDM4CTP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300987-A1 | TRAP1 INHIBITOR AND USE THEREOF | UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) | 2024-09-12 | — | — | US | disclosed |
| EP-4357351-A1 | TRAP1 INHIBITOR AND USE THEREOF | Smartin Bio Inc. (KR) | 2024-04-24 | — | — | EP | disclosed |
| CN-117769559-A | TRAP1 inhibitors and uses thereof | 斯玛特恩生物公司 | 2024-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300987-A1 | TRAP1 INHIBITOR AND USE THEREOF | TRAP1, PPP1R7, PPP1R15A | MEN1 1736/4885KMT2A 3900/4885KDM4C 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.